Get the Stockscreener App
3.00
0.66%
-0.02
Clene Inc stock is traded at $3.00, with a volume of 15,335.
It is down -0.66% in the last 24 hours and down -34.21% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$3.02
Open:
$3.04
24h Volume:
15,335
Relative Volume:
0.32
Market Cap:
$26.58M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-0.6726
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
-1.32%
1M Performance:
-34.21%
6M Performance:
-43.82%
1Y Performance:
-55.83%
1-Day Range:
$2.88
$3.04
1-Week Range:
$2.76
$3.18
52-Week Range:
$2.57
$9.20
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.00 | 26.58M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
29.46 | 35.56B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
57.51 | 32.31B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.37 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
75.32 | 20.81B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.58 | 16.80B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - Bluefield Daily Telegraph
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Breakthrough: New MS Drug Actually Repairs Brain Damage, Trial Data Shows 90% Success Rate - Stock Titan
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - Barchart.com
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com India
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
Top Nanotechnology Stocks To ConsiderMarch 15th - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
H.C. Wainwright maintains Clene stock Buy rating, $31 target By Investing.com - Investing.com South Africa
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):